Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study
Michel Attal(Université Fédérale de Toulouse Midi-Pyrénées), Michel Pavic(University of Bologna), Andrew Spencer(The Alfred Hospital), Richard LeBlanc(Hôpital Maisonneuve-Rosemont), Franck Dubin(Sanofi (France)), Philip Vlummens, Jesús F. San Miguel(Clinica Universidad de Navarra), Kathryn P. Corzo(AVEO Oncology (United States)), Wojciech Janowski, Ivan Špıčka(Charles University), H. Miles Prince(Peter MacCallum Cancer Centre), Kenneth C. Anderson(Dana-Farber Cancer Institute), Meral Beksaç(Ankara University), Meletios Α. Dimopoulos(Korea University), Ka Lung Wu, Paul G. Richardson(Harvard University), Karel Fostier, Ian Kerridge(The University of Sydney), Xavier Leleu(Inserm), Jiří Minařík(University Hospital Olomouc), S. Vincent Rajkumar(WinnMed), Michèle Cavo(Unknown), Fredrik Schjesvold(Oslo University Hospital), Sandrine Macé(Sanofi (France)), Simon J. Harrison(Peter MacCallum Cancer Centre), Michel Delforge(KU Leuven), Philippe Moreau(Centre National de la Recherche Scientifique), Jeffrey Shang-Yi Huang(National Taiwan University Hospital), Frank Campana(AVEO Oncology (United States)), Solenn Le-Guennec(Sanofi (France))
Cited by 635
Related Papers
International Staging System for Multiple Myeloma
|Journal of Clinical Oncology|2005|2.9k
A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma
|New England Journal of Medicine|2003|2.6k
International uniform response criteria for multiple myeloma
|Leukemia|2006|2.6k
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group
|Journal of Clinical Oncology|2015|2.2k
Hematological findings and complications of <scp>COVID</scp>‐19
|American Journal of Hematology|2020|1.7k